Adheris Health Limited

As of June 30, 2024, Adheris Health Limited carries a market capitalization of 275.27M, placing it among publicly traded companies globally. Its enterprise value stands at 272.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Adheris Health Limited's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2024, Adheris Health Limited has 550.54M shares outstanding.

As of June 30, 2024, Adheris Health Limited trades at a trailing price-to-earnings ratio of 345.98. The price-to-sales ratio is 2.24, and the price-to-book ratio stands at 5.34.

As of June 30, 2024, Adheris Health Limited trades at an EV/EBITDA multiple of 39.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 100.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 272.30M versus a market cap of 275.27M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Adheris Health Limited maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.44, indicating elevated leverage, while an interest coverage ratio of 3.57 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Adheris Health Limited posted a return on equity (ROE) of 1.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.89, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2024, Adheris Health Limited recorded 131,450.00 in income tax expense. That works out to an effective tax rate of 14.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 923,583.00, leaving 792,133.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 16, 2026, Adheris Health Limited's stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2024, Adheris Health Limited generated 122.11M in revenue and converted that into 792,133.00 in net income, yielding earnings per share of 0.00. EBITDA reached 6.89M, while operating income came in at 2.70M.

As of June 30, 2024, Adheris Health Limited holds 15.58M in cash and equivalents against 12.61M in total debt, resulting in a net debt position of -3.23M. Total book value stands at 51.58M, with working capital of -13.16M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Adheris Health Limited posted a gross margin of 60.81, reflecting its pricing power and cost economics. The operating margin of 2.21 and net profit margin of 0.65 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield reaches 0.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Adheris Health Limited shareholders.

Adheris Health Limited's most recent stock split took place on November 12, 2020 with a 69:70 split ratio.

As of June 30, 2024, Adheris Health Limited has an Altman Z-Score of 3.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.